NASDAQ: AEMDAethlon Medical Inc Stock
$2.02+0.12 (+6.32%)
Updated Jun 12, 2026
AEMD Price
$2.02
Fair Value Price
N/A
Market Cap
$4.79M
52 Week Low
$1.36
52 Week High
$27.40
P/E
-0.19x
P/B
0.98x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.15M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.3
Operating Cash Flow
-$7M
Beta
0.95
Next Earnings
Jun 24, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AEMD Overview
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AEMD's potential to beat the market
- AEMD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
AEMD
RankedUnranked of 94
RankedUnranked of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.51 | A | |
| $37.14 | A | |
| $26.31 | A |
Be the first to know about important AEMD news, forecast changes, insider trades & much more!
AEMD News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AEMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AEMD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AEMD is good value based on its book value relative to its share price (0.98x), compared to the US Medical Devices industry average (2.98x)
P/B vs Industry Valuation
AEMD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AEMD due diligence checks available for Premium users.
Valuation
AEMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.19x
Industry
20.73x
Market
14.15x
AEMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.98x
Industry
2.98x
AEMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AEMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
AEMD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$6.3M
Liabilities
$1.4M
Debt to equity
0.3
AEMD's short-term assets ($5.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AEMD's short-term assets ($5.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AEMD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AEMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
-$2.1k
Financing
-$196.5k
AEMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AEMD vs Medical Device Stocks
Aethlon Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.